金斯瑞生物科技（01548.HK）今日盘中大跌5.19%，引起市场广泛关注。该公司昨日公布了截至2025年6月30日的中期业绩，虽然亏损有所收窄，但仍未能扭亏为盈。
根据公告，金斯瑞生物科技上半年收益录得5.19亿美元，同比大幅增长81.9%。公司亏损由去年同期的1.75亿美元收窄至2,546万美元，每股亏损1.18美仙。尽管业绩有所改善，但公司决定不派发中期股息。
分析人士指出，尽管金斯瑞生物科技的收入显著增长，主要得益于礼新带来的分许可收益，但投资者可能对公司仍未能实现盈利感到失望。此外，生物科技行业的整体市场环境和投资者情绪也可能影响了股价表现。公司未来的盈利前景和研发进展将是投资者持续关注的焦点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.